Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Monday morning. The brokerage issued a hold rating on the medical research company’s stock.

CTSO has been the subject of several other reports. HC Wainwright reiterated a neutral rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Wednesday, August 14th. EF Hutton Acquisition Co. I upgraded shares of Cytosorbents to a strong-buy rating in a report on Monday, July 29th.

Cytosorbents Price Performance

CTSO stock opened at $1.52 on Monday. The firm has a 50-day moving average of $1.09 and a 200 day moving average of $0.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.12 and a quick ratio of 1.71. The company has a market cap of $82.55 million, a P/E ratio of -2.58 and a beta of 0.50. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $2.15.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The company had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $9.73 million. Cytosorbents had a negative return on equity of 131.84% and a negative net margin of 68.70%. During the same quarter last year, the business posted ($0.14) EPS. On average, sell-side analysts forecast that Cytosorbents will post -0.32 EPS for the current year.

Institutional Trading of Cytosorbents

A number of institutional investors and hedge funds have recently bought and sold shares of CTSO. Avenir Corp raised its stake in shares of Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after purchasing an additional 121,294 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in shares of Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after acquiring an additional 299,103 shares during the last quarter. Sargent Investment Group LLC grew its stake in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after acquiring an additional 67,181 shares during the period. CM Management LLC raised its holdings in shares of Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Key Client Fiduciary Advisors LLC boosted its holdings in Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after purchasing an additional 22,557 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.